Efficacy of gemcitabine in combination with nanoparticle albumin-bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review.

Autor: Kase AM; Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA., Azzouqa AG; Cancer Care Institute, Monument Health, Rapid City, South Dakota, USA., Kochuveettil S; Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA., Colon-Otero G; Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA.
Jazyk: angličtina
Zdroj: Cancer medicine [Cancer Med] 2023 Apr; Vol. 12 (8), pp. 9434-9438. Date of Electronic Publication: 2023 Feb 21.
DOI: 10.1002/cam4.5705
Abstrakt: Background: The objective of this study was to evaluate the efficacy of gemcitabine plus nab-paclitaxel in patients with recurrent ovarian cancer.
Methods: We performed a single institution retrospective review of patients with recurrent ovarian cancer who were treated with gemcitabine plus nab-paclitaxel from 2012 to 2018 at the Mayo Clinic in Florida.
Results: Twenty patients were identified and the median PFS for patients treated with gemcitabine plus nab-paclitaxel was 9 months (95% CI, 5.7-20.7). Overall, 17 of the 20 patients (85%) achieved a clinical benefit (complete response 5%, partial response 55%, or stable disease at 3 months 25%). For platinum-sensitive disease and platinum-resistant disease, the median OS were 38.7 months (95% CI, 5.8-63.1) and 31.2 months (95% CI, 12.8-51.8), respectively (p = 0.4306).
Conclusion: This well-tolerated regimen shows promising activity in recurrent ovarian cancer and is a viable option for patients who are intolerant to paclitaxel or carboplatin because of allergic reactions.
(© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje